GlassScriptPhysician profile
Rachael Kermis
NPI 1265886303
$1,852.62
in general payments reported to CMS, 2019-2025
21 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $187 · 2021: $334 · 2022: $737 · 2023: $350 · 2024: $21.15 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $261.62 | 2020-2023 | Farxiga |
| Novo Nordisk INC | $235.69 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $174.69 | 2022 | |
| Esperion Therapeutics, INC. | $150.30 | 2020-2022 | |
| Abbvie INC. | $149.74 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.21 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.83 | 2022 | |
| Gilead Sciences, INC. | $121.83 | 2025 | Yeztugo |
| Lilly USA, LLC | $112.47 | 2021-2023 | Mounjaro |
| Mannkind Corporation | $59.40 | 2022 | |
| Amgen INC. | $54.51 | 2021-2022 | |
| Allergan, INC. | $48.05 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.96 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.56 | 2022 | |
| Abbott Laboratories | $39.09 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $24.01 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $21.15 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $17.62 | 2022 | |
| Antares Pharma, INC. | $17.26 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.07 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Kermis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.